NTP 42
Alternative Names: NTP-42; NTP42:KVA4Latest Information Update: 10 Dec 2024
At a glance
- Originator ATXA Therapeutics
- Developer ATXA Therapeutics; Hammersmith Medicines Research
- Class Antihypertensives; Antineoplastics; Cardiovascular therapies; Heart failure therapies; Small molecules
- Mechanism of Action Thromboxane A2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Pulmonary arterial hypertension
- Preclinical Cardiovascular disorders; Heart failure
- Research Cancer; Genitourinary disorders
Most Recent Events
- 10 Dec 2024 ATXA Therapeutics plans a phase II trial for Pulmonary arterial hypertension in Europe and North America (ATXA Therapeutics website, December 2024)
- 09 Dec 2024 Phase I development is ongoing for Pulmonary arterial hypertension (PO, Suspension) in United Kingdom (ATXA Therapeutics pipeline, December 2024)
- 09 Dec 2024 ATXA Therapeutics has patent protection for thromboxane receptor antagonists in the US, the European Union, Australia, Japan and Canada (ATXA Therapeutics website, December 2024)